Ocugen, Inc. (OCGN): R&D Expense

Annual figures by period end, from SEC filings.

Restated years: each year's figure is from the latest filing that reports it. The company later restated the year ended 2018-12-31 (for example after a spin-off or a discontinued operation), while the year before it was last reported on the old basis. Changes across those points are marked n/c (not comparable), and growth rates are not computed across them.

$39.75M

Year ended 2025-12-31

$43.76M

Trailing 12 months to 2026-06-30

2014-12-31 R&D Expense (USD) 2025-12-31

Period ended	R&D Expense	Change YoY	Source filing
2025-12-31	$39.75M	+23.7%	2026-03-04, From 2025-01-01
2024-12-31	$32.13M	-18.8%	2026-03-04, From 2024-01-01
2023-12-31	$39.57M	n/a	2025-03-05, From 2023-01-01
No annual figure between 2019-12-31 and 2023-12-31.
2019-12-31	$8.09M	-21.7%	2020-03-27, From 2019-01-01
2018-12-31	$10.32M	n/c	2020-03-27, From 2018-01-01
2017-12-31	$15.57M	-27.9%	2019-03-22, From 2017-01-01
2016-12-31	$21.58M	-7.2%	2018-03-15, From 2016-01-01
2015-12-31	$23.24M	-10.7%	2017-03-16, From 2015-01-01
2014-12-31	$26.04M	n/a	2016-03-10, From 2014-01-01

R&D Expense at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	R&D Expense	Change YoY
Ocugen, Inc. (OCGN)	2025-12-31	$39.75M	+23.7%
Prime Medicine, Inc. (PRME)	2025-12-31	$160.64M	+3.4%
CG Oncology, Inc. (CGON)	2025-12-31	$116.64M	+42.1%
Zeo ScientifiX, Inc. (ZEOX)	2025-10-31	$100.0K	-39.0%
CRISPR Therapeutics AG (CRSP)	2025-12-31	$284.81M	-8.2%
Surrozen, Inc. (SRZN)	2025-12-31	$29.36M	+39.0%
DBV Technologies S.A. (DBVT)	2025-12-31	$116.68M	+30.6%
Dyadic International Inc (DYAI)	2025-12-31	$2.15M	+5.4%
Fate Therapeutics Inc (FATE)	2025-12-31	$107.83M	-20.1%

Compare OCGN, PRME, CGON, ZEOX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗